ENDEAVOUR

Morgan Stanley in a research note released Monday noted that the Data Monitoring Committee has recommended Alnylam Pharmaceuticals, Inc.(NASDAQ: ALNY) continue with the trail without modification, following examination of safety data from the Phase III hATTR-PN trial. That said, the firm believes...